Abstract. Trans fatty acids (TFAs) are risk factors for cardiovascular disorders, and the cancer-promoting effects of TFAs have been previously reported. The present study examined the effects and signaling of elaidic acid (EA), a TFA, in colorectal cancer (CRC) cells. Oral intake of EA was found to increase metastasis of HT29 human CRC cells. Results indicated that, in the plasma membrane, EA was integrated into cholesterol rafts, which contain epidermal growth factor receptors (EGFR). EA increased nanog and c-myc, and decreased PGC-1A through lipid raft-associated EGFR signaling in HT29 cells. Depletion of cholesterol by methyl-β-cyclodextrin treatment abrogated the EA-induced stemness and oxidative phosphorylation. Simvastatin treatment also abrogated EA-enhanced tumor growth. These results indicate that EA enhances the stemness by activating EGFR in lipid rafts.
Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in Japan (1), and its incidence has been reported to be increasing because of the popularity of western lifestyle (2, 3) . We have previously reported the pro-tumoral effects of elaidic acid (EA), a major trans fatty acid (TFA) (4, 5) . EA is a long-chain fatty acid (LCFA) containing 18 carbon chains in a trans configuration, and is a structural isomer of oleic acid (OA). EA promotes carcinogenesis in Min mice (6) and induces the proliferation of Ehrlich ascites sarcoma cells (7) . EA enhances the metastasis of CRC in mouse models (4) by increasing cancer cell stemness and epithelial-mesenchymal transition (EMT) (5) . EA also induces chemoresistance in CRC cells by upregulating its stemness (8) .
LCFAs bind to specific membrane-bound receptors, namely, G-protein coupled receptor 40 (GPR40) and GPR120 (9) . EA also binds to GPR40 and 120, inducing the transactivation of EGFR via c-src (5) . Lipid rafts represent a special localization of epidermal growth factor receptors (EGFRs), altering its signaling pathways (10) and transactivation (11) . Rao et al have reported that EA can affect Fas/FasL-induced apoptosis via lipid rafts (12) . Lipid rafts may play an important role in EGFR signaling in EA-treated cells.
In the present study, we examined the effect of EA on pro-metastatic EGFR signals that may be associated with cholesterol rafts.
Materials and methods
Cell culture and reagents. HT29, a human colon cancer cell line, was purchased from Dainihon Pharmacy Co. (Tokyo, Japan). The cells were routinely maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (both Sigma, St. Louis, MO, USA) in 5% CO 2 at 37˚C. Cell morphology was evaluated daily by microscopic examination. Each cell line was routinely tested for Mycoplasma contamination by genomic PCR. The viability of each cell line was tested by trypan blue exclusion assay.
EA (CAS no. 112-79-8), OA (CAS no. 112-80-1; both WAKO Pure Chemicals, Osaka, Japan), and methyl-β-cyclodextrin (MbCD; Sigma) were purchased from the mentioned suppliers.
Cell membrane cholesterol was depleted by incubating the cells in a sterile-filtered MbCD medium (RPMI-1640 medium supplemented with 10 mM MbCD and cholesterol-free serum; Sigma).
Assessment of cell growth. The cells (1x10 4 per well) were seeded in a 12-well dish. Cell growth was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or by counting the number of cells with an Autocytometer (Sysmex, Kobe, Japan) after 48 h, as described previously (13 For analyzing the metastasis to the liver, lung, and peritoneum, cancer cells (1x10 6 cells) were inoculated into the spleen, the tail vein, or peritoneal cavity, respectively. EA or OA were administrated through a gavage. The growth of subcutaneous tumors and the metastatic status of the cells was assessed after 4 weeks. For assessing growth of subcutaneous tumors, the diameters of the tumors were measured every week. For peritoneal metastasis, the weight of mesenterium with tumors was measured. For metastases to the liver and lung, the number of tumors at the organ surface was counted. Simvastatin (50 mg/kg/day; WAKO) was administrated through a gavage for 10 days after the inoculation of cancer cells.
Western blot analysis. Whole-cell lysates were prepared as described previously (14) . Cell fractions were extracted by processing the cells with the Cell Fractionation kit (Abcam, Cambridge, MA, USA), according to the manufacturer's instructions.
Proteins (20 µg) were separated from the cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 12.5% gels. They were then electrotransferred onto nitrocellulose membranes for immunoblotting analysis. The membranes were incubated with primary antibodies, followed by incubation with peroxidase-conjugated IgG antibodies (Medical & Biological Laboratories Co., Ltd, Nagoya, Japan). A tubulin antibody (Oncogene Research Products, Cambridge, MA, USA) was used to measure the amount of proteins loaded in each lane. Immune complexes were visualized using the CSA system (DAKO, Carpinteria, CA, USA). Antibodies against EGFR (Transduction Laboratories, Lexington, KY, USA), phosphorylated EGFR, phosphorylated ERK1/2 (pThr 204 ), nanog (clone 1E6C4), c-Myc (clone 9E10; Santa Cruz Biotechnology, Santa Cruz, CA, USA), phosphorylated p38 (pThr 180 /pTyr 182 ; Bioss Inc., Woburn, MA, USA), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1A; Proteintech Group, Inc., Rosemount, IL, USA) were used as primary antibodies.
Extraction of raft fractions. Lipid rafts were isolated from 5x10 7 cells. Briefly, cell pellets disrupted in 1 ml buffer A [50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , 0.15 M NaCl, 1% Triton X-100, 5% glycerol, 50 mM PMSF, 1x protease inhibitor cocktail (Sigma), and 0.03% β-mercaptoethanol] were centrifuged for 5 min at 500 x g and 4˚C. The obtained supernatant was added to 1 ml buffer A [50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , 0.15 M NaCl, and 80% sucrose] to make up the final concentration of sucrose to 40%. A discontinuous sucrose gradient was obtained by stratifying 7.5 ml buffer A with 38% sucrose and 2 ml buffer A with 15% sucrose. The gradient was ultracentrifuged for 18 h at 100,000 x g and 4˚C.
Twelve fractions (1 ml each) were collected from the top to the bottom of the gradient (F1-F12). Immunoblotting analysis was performed to identify the fractions containing lipid rafts. Cholesterol levels were measured using the Amplex Red cholesterol assay kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Statistical analysis. Statistical analyses of experimental data were performed using the Mann-Whitney U test or the Kruskal-Wallis test with Dunn's multiple comparison (nonparametric ANOVA). Differences with a two-sided P-value <0.05 were considered to indicate a statistically significant difference.
Results

EA enhances metastasis.
The HT29 cells were inoculated into the subcutaneous tissue, spleen (liver metastasis), tail vein (lung metastasis), and peritoneum of nude mice treated with EA, OA, or control vehicle by gavage administration (Fig. 1) . The EA-treated mice showed higher growth of subcutaneous tumors and metastases to liver, lungs, and peritoneum than control mice. In contrast, only peritoneal metastasis was increased in the OA-treated mice, compared to the control mice.
EA activates EGFR in lipid rafts.
We examined the integration of EA into lipid rafts ( Fig. 2A) . We observed that EA was preferentially integrated into cholesterol rafts, significantly increasing their cholesterol content (Fig. 2B) . In contrast, MbCD preferentially decreased the cholesterol content of EA-induced rafts ( Fig. 2A) . EA integration into cholesterol rafts upregulated the accumulation and induced the phosphorylation of EGFR (Fig. 2B) . In contrast, MbCD suppressed EA-induced phosphorylation of EGFR and ERK1/2 (Fig. 2C, D) . Furthermore, the levels of phosphorylated p38 were higher than the levels of phosphorylated ERK1/2 in cholesterol-raft depleted cells (Fig. 2D) . Effect of EA on cancer stem cell-proteins. Next, we examined the role of lipid rafts on the stemness of cancer cells, which is known to be enhanced by EA (5) . EA treatment increased nanog production in HT29 cells; however, it was abrogated by cholesterol depletion after MbCD treatment (Fig. 3A) . c-Myc protein levels were also increased by EA treatment and abrogated by cholesterol depletion. In contrast, PGC-1A levels were decreased by EA and abrogated by cholesterol depletion.
Simvastatine, which has been reported to deplete lipid rafts in a cholangiocarcinoma mouse model (15) , was administrated to the EA-treated mice. In the subcutaneous HT29 cell tumor model, lipid raft depletion inhibited the EA-induced tumor growth (Fig. 3B) . The tumor growth rate in the simvastatine and EA-treated mice was lower than that in the EA-treated mice and even than that in the control mice.
Discussion
Results of the present study indicated that EA could strongly enhance cancer metastasis by increasing their stemness via EGFR activation in lipid rafts.
In our data, HT29 cells showed enhanced metastasis after EA gavage administration. EA activated EGFRs, as reported in our previous report (5); however, it was important that EA-induced EGFR signals disappeared after the absorbance of cholesterol, which caused lipid raft depletion. Raft depletion also abrogated the EA-induced expression of nanog and c-myc. These findings suggested that EA-associated signal pathways may prefer lipid rafts.
EA can be incorporated into plasma membranes composed of stearic or palmitic acid, to be subsequently converted into triglycerides (16), cholesterol esters, phospholipids, or other LCFAs such as OA and LA (17). Our results were consistent with the findings of these studies; we observed that EA could easily integrate into the plasma membrane, especially cholesterol rafts, of CRC cells.
We found that lipid rafts played an important role in EA signaling. Lipid rafts are microdomains within the lipid bilayer of cellular membranes. Levels of non-constitutive proteins in lipid rafts fluctuate dramatically in different cancers, affecting various signaling pathways (18) . We have previously reported that EA binds to GPR40 and GPR120, which signals SRC-mediated crosstalk to EGFRs (5). Another previous study had shown that the crosstalk between GPRs and EGFRs in the raft could activate phospholipases C, D, and A2, which could activate protein kinase C, ERK, and Akt (19) . Lipid rafts are known to be thicker than the surrounding membrane and the propensity of EGFR to be located in rafts is characterized by a thick lipid bilayer (35.0 Å) around the transmembrane segment of the receptor (20) .
The raft-associated EA signal upregulated nanog and c-Myc, while it downregulated PGC-1A. c-Myc is associated with cell proliferation and aerobic glycolysis, and PGC-1A is associated with stemness and oxidative phosphorylation (21, 22) . The upregulation of nanog in the present data and our previous data (5) indicated that EA increased the stemness of cancer cells; however, the cancer cells may have been of a proliferative nature with glycolytic energy metabolism, which is different from dormant stem cells that possess oxidative phosphorylation metabolism. The induction of proliferative cancer stem cells may be the most striking characteristic of EA to enhance cancer metastasis.
We observed that cholesterol depletion inhibited EA-enhanced tumor growth below the level of untreated tumors in the subcutaneous tumor mouse model. Importantly, lipid raft depletion may inhibit EGFR signals in the presence or absence of EA. Statins have been reported to inhibit the growth of JAK2-mutated cells by inhibiting lipid rafts (23) and inducing apoptosis by inhibiting Rac1 (15) . Thus, lipid rafts act as a platform for collecting multiple stimulants, receptors, and signals to activate cancer progression (24) . The mechanism of integration of EA to cholesterol raft should be elucidated in further examinations; however, our data suggests that lipid rafts may be promising targets for anticancer treatment.
